{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:14Z","timestamp":1792783214439,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007700","name":"Universitatea de Medicin\u0103 \u015fi Farmacie \"Carol Davila\" Bucure\u015fti","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007700","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Recordati Rare Diseases","id":[{"id":"https:\/\/ror.org\/00x68eg25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Somatotroph pituitary adenomas are a heterogeneous group comprising distinct histopathological subtypes, including the well-defined densely granulated (DG) and sparsely granulated (SG) phenotypes. While the aryl hydrocarbon receptor-interacting protein (AIP) pathway has been implicated in pituitary tumorigenesis, the role of aryl hydrocarbon receptor nuclear translocator (ARNT) in somatotroph tumors remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 71 surgically treated somatotroph pituitary adenomas, clinically managed in a tertiary endocrinology center between 2020 and 2025. Immunohistochemical expression of AIP, AHR and ARNT was evaluated and correlated with clinicopathological characteristics, including cytokeratin pattern, hormonal expression and Ki-67 index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Moderate\/strong ARNT expression was more frequent in SG than in DG adenomas (60% vs. 17.6%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). Patients with moderate\/strong ARNT expression were younger than those with absent\/weak expression (median 39 vs. 46 years,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044). In multivariable analysis, ARNT expression remained associated with the SG phenotype after adjustment for age and sex (adjusted OR 6.84, 95% CI 2.05\u201322.84;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). No significant associations were observed between ARNT expression and Ki-67 index, baseline GH or IGF1 levels, AIP\/AHR immunoexpression or the evaluated clinical outcomes, including biochemical control during first-generation somatostatin receptor ligand therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Increased ARNT expression is associated with the sparsely granulated phenotype in somatotroph pituitary adenomas, suggesting that ARNT expression may reflect tumor differentiation rather than proliferative activity. However, the present findings do not demonstrate additional prognostic or therapeutic utility beyond granulation pattern. Further molecular and transcriptomic studies are warranted to clarify the biological role of ARNT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01776-5","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:25:42Z","timestamp":1792200342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher ARNT expression is associated with the sparsely granulated phenotype in somatotroph pituitary adenomas: An immunohistochemical study"],"prefix":"10.1007","volume":"29","author":[{"given":"Cristiana","family":"C\u0103lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia Florentina","family":"Burcea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Dobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana-Ioana Dumitriu","family":"Stan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Alin","family":"Publik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Cristina","family":"Terzea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihail-Constantin","family":"Ceau\u0219u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina","family":"Poian\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"11","key":"1776_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10(11):804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1776_CR2","unstructured":"WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine Tumours. WHO Classification of Tumours, 5th ed., Vol. 10. Lyon: International Agency for Research on Cancer (2025) ISBN 978-92-832-4524-7"},{"issue":"11","key":"1776_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-023-00883-8","volume":"19","author":"KKY Ho","year":"2023","unstructured":"Ho KKY, Kaiser UB, Chanson P et al (2023) Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification. Nat Rev Endocrinol 19(11):671\u2013678. https:\/\/doi.org\/10.1038\/s41574-023-00883-8","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1776_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","volume":"76","author":"SL Fougner","year":"2012","unstructured":"Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76(1):96\u2013102. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04163.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1776_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","volume":"16","author":"J Brzana","year":"2013","unstructured":"Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M (2013) Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 16(4):490\u2013498. https:\/\/doi.org\/10.1007\/s11102-012-0445-1","journal-title":"Pituitary"},{"issue":"1","key":"1776_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","volume":"49","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Carlson NE, Borges MT et al (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1):231\u2013241. https:\/\/doi.org\/10.1007\/s12020-014-0383-y","journal-title":"Endocrine"},{"issue":"2","key":"1776_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","volume":"24","author":"AA Swanson","year":"2021","unstructured":"Swanson AA, Erickson D, Donegan DM et al (2021) Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary 24(2):192\u2013206. https:\/\/doi.org\/10.1007\/s11102-020-01096-2","journal-title":"Pituitary"},{"issue":"5777","key":"1776_CR8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1126\/science.1126100","volume":"312","author":"O Vierimaa","year":"2006","unstructured":"Vierimaa O, Georgitsi M, Lehtonen R et al (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228\u20131230. https:\/\/doi.org\/10.1126\/science.1126100","journal-title":"Science"},{"issue":"6","key":"1776_CR9","doi-asserted-by":"publisher","first-page":"e2247","DOI":"10.1210\/clinem\/dgaa040","volume":"105","author":"P Marques","year":"2020","unstructured":"Marques P, Caimari F, Hern\u00e1ndez-Ram\u00edrez LC et al (2020) Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. J Clin Endocrinol Metab 105(6):e2247\u2013e2260. https:\/\/doi.org\/10.1210\/clinem\/dgaa040","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1776_CR10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1677\/ERC-09-0094","volume":"16","author":"ML Jaffrain-Rea","year":"2009","unstructured":"Jaffrain-Rea ML, Angelini M, Gargano D et al (2009) Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer 16(3):1029\u20131043. https:\/\/doi.org\/10.1677\/ERC-09-0094","journal-title":"Endocr Relat Cancer"},{"key":"1776_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2119\/molmed.2014.00032","volume":"20","author":"M Mandl","year":"2014","unstructured":"Mandl M, Depping R (2014) Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1\u03b2): is it a rare exception? Mol Med 20:215\u2013220. https:\/\/doi.org\/10.2119\/molmed.2014.00032","journal-title":"Mol Med"},{"issue":"6","key":"1776_CR12","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.2353\/ajpath.2009.081131","volume":"175","author":"E Heli\u00f6vaara","year":"2009","unstructured":"Heli\u00f6vaara E, Raitila A, Launonen V et al (2009) The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am J Pathol 175(6):2501\u20132507. https:\/\/doi.org\/10.2353\/ajpath.2009.081131","journal-title":"Am J Pathol"},{"issue":"4","key":"1776_CR13","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2353\/ajpath.2010.100138","volume":"177","author":"A Raitila","year":"2010","unstructured":"Raitila A, Lehtonen HJ, Arola J et al (2010) Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am J Pathol 177(4):1969\u20131976. https:\/\/doi.org\/10.2353\/ajpath.2010.100138","journal-title":"Am J Pathol"},{"issue":"11","key":"1776_CR14","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JAH (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"key":"1776_CR15","unstructured":"Ministry of Health of Romania; National Health Insurance House (2021) Order No. 564\/499\/2021 approving the therapeutic protocols for the prescription of medicines, including therapeutic protocol H005E: Acromegaly and gigantism. Monitorul Oficial al Rom\u00e2niei"},{"issue":"5","key":"1776_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"issue":"4","key":"1776_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610\u2013617. https:\/\/doi.org\/10.1227\/00006123-199310000-00008","journal-title":"Neurosurgery"},{"issue":"11","key":"1776_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","volume":"21","author":"S Melmed","year":"2025","unstructured":"Melmed S, di Filippo L, Fleseriu M et al (2025) Consensus on acromegaly therapeutic outcomes: an update. Nat Rev Endocrinol 21(11):718\u2013737. https:\/\/doi.org\/10.1038\/s41574-025-01148-2","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1776_CR19","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvaf100","volume":"192","author":"G Raverot","year":"2025","unstructured":"Raverot G, Burman P, Abreu AP et al (2025) Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas. Eur J Endocrinol 192(6):G1\u2013G34. https:\/\/doi.org\/10.1093\/ejendo\/lvaf100","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1776_CR20","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.3390\/jcm10112254","volume":"10","author":"SL Asa","year":"2021","unstructured":"Asa SL, Ezzat S (2021) An update on pituitary neuroendocrine tumors leading to acromegaly. J Clin Med 10(11):2254. https:\/\/doi.org\/10.3390\/jcm10112254","journal-title":"J Clin Med"},{"issue":"4","key":"1776_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12672-017-0300-y","volume":"8","author":"R Formosa","year":"2017","unstructured":"Formosa R, Vassallo J (2017) The complex biology of the aryl hydrocarbon receptor and its role in the pituitary gland. Horm Cancer 8(4):197\u2013210. https:\/\/doi.org\/10.1007\/s12672-017-0300-y","journal-title":"Horm Cancer"},{"key":"1776_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1159\/000354487","volume":"32","author":"M Wolff","year":"2013","unstructured":"Wolff M, Jelkmann W, Dunst J, Depping R (2013) The aryl hydrocarbon receptor nuclear translocator (ARNT\/HIF-1\u03b2) is influenced by hypoxia and hypoxia-mimetics. Cell Physiol Biochem 32:849\u2013858. https:\/\/doi.org\/10.1159\/000354487","journal-title":"Cell Physiol Biochem"},{"issue":"19","key":"1776_CR23","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMra2409076","volume":"393","author":"A Giustina","year":"2025","unstructured":"Giustina A, Colao A, Acromegaly (2025) N Engl J Med 393(19):1926\u20131939. https:\/\/doi.org\/10.1056\/NEJMra2409076","journal-title":"N Engl J Med"},{"key":"1776_CR24","doi-asserted-by":"publisher","first-page":"110445","DOI":"10.1016\/j.cellsig.2022.110445","volume":"99","author":"A Salminen","year":"2022","unstructured":"Salminen A (2022) Mutual antagonism between aryl hydrocarbon receptor and hypoxia-inducible factor-1\u03b1 (AhR\/HIF-1\u03b1) signaling: impact on the aging process. Cell Signal 99:110445. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110445","journal-title":"Cell Signal"},{"issue":"8","key":"1776_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1530\/ERC-17-0112","volume":"24","author":"R Formosa","year":"2017","unstructured":"Formosa R, Borg J, Vassallo J (2017) Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in pituitary adenomas. Endocr Relat Cancer 24(8):445\u2013457. https:\/\/doi.org\/10.1530\/ERC-17-0112","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"1776_CR26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/onc.2014.50","volume":"34","author":"I Tuominen","year":"2015","unstructured":"Tuominen I, Heliovaara E, Raitila A et al (2015) AIP inactivation leads to pituitary tumorigenesis through defective G alpha(i)-cAMP signaling. Oncogene 34(9):1174\u20131184. https:\/\/doi.org\/10.1038\/onc.2014.50","journal-title":"Oncogene"},{"key":"1776_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1530\/ERC-12-0322","volume":"20","author":"ML Jaffrain-Rea","year":"2013","unstructured":"Jaffrain-Rea ML, Rotondi S, Turchi A et al (2013) Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr Relat Cancer 20:753\u2013766. https:\/\/doi.org\/10.1530\/ERC-12-0322","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"1776_CR28","doi-asserted-by":"publisher","first-page":"L25","DOI":"10.1530\/ERC-12-0020","volume":"19","author":"L Kasuki","year":"2012","unstructured":"Kasuki L, Vieira Neto L, Wildemberg LEA et al (2012) AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer 19(3):L25\u2013L30. https:\/\/doi.org\/10.1530\/ERC-12-0020","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"1776_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1530\/EC-19-0027","volume":"8","author":"AF Daly","year":"2019","unstructured":"Daly AF, Cano DA, Venegas-Moreno E et al (2019) AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. Endocr Connect 8(4):338\u2013348. https:\/\/doi.org\/10.1530\/EC-19-0027","journal-title":"Endocr Connect"},{"issue":"7","key":"1776_CR30","doi-asserted-by":"publisher","first-page":"e28231","DOI":"10.1016\/j.heliyon.2024.e28231","volume":"10","author":"AL Shen","year":"2024","unstructured":"Shen AL, Moran SM, Glover EN et al (2024) Familial isolated pituitary adenoma is independent of Ahr genotype in a novel mouse model of disease. Heliyon 10(7):e28231. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28231","journal-title":"Heliyon"},{"issue":"3","key":"1776_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","volume":"59","author":"M Kato","year":"2012","unstructured":"Kato M, Inoshita N, Sugiyama T et al (2012) Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 59(3):221\u2013228. https:\/\/doi.org\/10.1507\/endocrj.EJ11-0177","journal-title":"Endocr J"},{"key":"1776_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1530\/EJE-13-0134","volume":"169","author":"B Mayr","year":"2013","unstructured":"Mayr B, Buslei R, Theodoropoulou M et al (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169:391\u2013400. https:\/\/doi.org\/10.1530\/EJE-13-0134","journal-title":"Eur J Endocrinol"},{"issue":"23","key":"1776_CR33","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3390\/cells11233846","volume":"11","author":"J Rymuza","year":"2022","unstructured":"Rymuza J, Kober P, Rusetska N et al (2022) Transcriptomic classification of pituitary neuroendocrine tumors causing acromegaly. Cells 11(23):3846. https:\/\/doi.org\/10.3390\/cells11233846","journal-title":"Cells"},{"key":"1776_CR34","doi-asserted-by":"publisher","first-page":"1423606","DOI":"10.3389\/fonc.2024.1423606","volume":"14","author":"K Kim","year":"2024","unstructured":"Kim K, Kim Y, Kim SH et al (2024) Differential gene expression and pathway analysis in growth hormone-secreting pituitary tumors according to granulation pattern. Front Oncol 14:1423606. https:\/\/doi.org\/10.3389\/fonc.2024.1423606","journal-title":"Front Oncol"},{"key":"1776_CR35","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","volume":"5","author":"A Yamato","year":"2022","unstructured":"Yamato A, Nagano H, Gao Y et al (2022) Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors. Commun Biol 5:1304. https:\/\/doi.org\/10.1038\/s42003-022-04272-1","journal-title":"Commun Biol"},{"key":"1776_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","volume":"37","author":"M Neou","year":"2020","unstructured":"Neou M, Villa C, Armignacco R et al (2020) Pangenomic classification of pituitary neuroendocrine tumors. Cancer Cell 37:123\u2013134e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.11.002","journal-title":"Cancer Cell"},{"key":"1776_CR37","doi-asserted-by":"publisher","first-page":"773905","DOI":"10.3389\/fonc.2021.773905","volume":"11","author":"C Dai","year":"2021","unstructured":"Dai C, Liang S, Sun B, Li Y, Kang J (2021) Anti-VEGF therapy in refractory pituitary adenomas and pituitary carcinomas: a review. Front Oncol 11:773905. https:\/\/doi.org\/10.3389\/fonc.2021.773905","journal-title":"Front Oncol"},{"key":"1776_CR38","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.3892\/or.2013.2689","volume":"30","author":"W Chen","year":"2013","unstructured":"Chen W, Xiao Z, Zhao Y, Huang L, Du G (2013) HIF-1\u03b1 inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression. Oncol Rep 30:2495\u20132501. https:\/\/doi.org\/10.3892\/or.2013.2689","journal-title":"Oncol Rep"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01776-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01776-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01776-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:25:44Z","timestamp":1792200344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01776-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01776-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of \u201cC. I. Parhon\u201d National Institute of Endocrinology, Bucharest, Romania (Approval No. 25\/19.07.2023).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"171"}}